汇宇制药(688553) - 2025 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2025 was RMB 998.15 million, a decrease of 8.79% compared to the previous year[3] - Operating profit was RMB -65.05 million, down 118.67% year-over-year[3] - Total profit amounted to RMB -63.13 million, reflecting a decline of 118.05% from the prior year[3] - Net profit attributable to shareholders of the parent company was RMB -24.20 million, a decrease of 107.44% compared to the previous year[3] - Basic earnings per share were RMB -0.06, down 107.79% year-over-year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 5,021.61 million, a decrease of 2.79% from the beginning of the period[3] - Shareholders' equity attributable to the parent company was RMB 3,758.96 million, down 5.53% from the beginning of the period[3] Performance Decline Factors - The decline in performance was primarily due to the implementation of centralized procurement policies, leading to reduced product prices and profits[6] Investment Gains - The company recognized a fair value change gain of RMB 173 million from its investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which was listed on the Hong Kong Stock Exchange during the reporting period[7] Financial Data Disclaimer - The company cautions investors that the financial data presented is preliminary and subject to final audit[10]